A STUDY ON TREATMENT OUTCOME OF LUPUS NEPHRITIS PATIENTS IN SOUTH INDIAN POPULATION

Introduction:

SLE is a chronic multifactorial autoimmune disease that affects many organs including kidney.

Lupus nephritis is characterized by heterogenous clinical and histopathological findings and often associates with poor prognosis. Although newer multi target therapies have evolved, this study was done to analyse the treatment outcome of two different cyclophosphamide based regimen in south Indian population

Methods:

STUDY DESIGN- RETROSPECTIVE STUDY

STUDY SETTING – A tertiary health care centre based study done in Tirunelveli medical college, Tirunelveli

45 out of 60 Lupus nephritis patients from January 2019 to August 2023 were included.

Treatment outcome in terms of complete, partial remission and no response was assessed in patients receiving NIH protocol (25) and Eurolupus regimen (20) according to KDIGO guidelines

Inclusion criteria – patients with class III,IV, class III/V, IV/V were included

Exclusion criteria- patients with class I,II,V Lupus were excluded

Statistical mathods: Data were entered in MS excel and analysis was done using SPSS 21.0 version. Data were presented as mean and standard deviation for continuous data and as percentages for categorical variables. Chi square or Fisher exact test was done to find out association between categorical variables. Unpaired t test was done to compare two group mean and ANOVA for more than two group means. p value of less than 0.05 was considered significant.

Results:

Among 60 patients, 45 patients had proliferative lupus. 25 patients were in NIH Regimen and 20 patients in Eurolupus regimen.23 patients (92%) in NIH and 14 patients in Eurolupus(70)  attained remission.2 patients in NIH and 5 patients in Eurolupus had no response.  8 patients in NIH(32%) and 6 patients (30%) in Eurolupus developed infections due to treatment. 5 patients in Eurolupus and 9 patients in NIH had flare

Conclusions:

Significant proteinuria reduction achieved in NIH regimen compared to Eurolupus regimen.

Higher rate of remission achieved in NIH regimen compared to Eurolupus regimen but statistically not significant(p=0.190).

Study on larger population may be needed to confirm our results.

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.